Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Core Insights - Genprex, Inc. announced that its research collaborators will present positive preclinical data on Reqorsa® Gene Therapy for lung cancer at the 2026 AACR Annual Meeting, highlighting its potential as a treatment for ALK-EML4 positive translocated non-small cell lung cancer [1][2] Group 1: Preclinical Data and Biomarkers - The presentation will include three distinct abstracts that provide robust preclinical evidence supporting Reqorsa's potential in cancer treatment, particularly focusing on TUSC2's therapeutic mechanisms [2] - TROP2 and PTEN have been identified as potential biomarkers for predicting patient response to TUSC2 gene therapy in non-small cell lung cancer, which could refine patient selection strategies [2] Group 2: Efficacy of Quaratusugene Ozeplasmid - Quaratusugene ozeplasmid (Quar Oze) has shown to induce apoptosis in ALK-positive models, demonstrating a 79% tumor shrinkage when combined with alectinib, compared to a 60% reduction with alectinib alone [4][5] - In resistant models, the combination of Quar Oze and alectinib produced a synergistic effect, achieving significant tumor reduction and improved overall survival [5] Group 3: Immune Response Enhancement - TUSC2 enhances NK cell cytotoxicity, with therapeutic delivery via Quar Oze suppressing tumor progression and driving complete tumor elimination in many cases [7] - In vivo studies showed that Quar Oze significantly increased NK cell degranulation and proliferation, supporting its role as an immunomodulatory tumor suppressor [6][7] Group 4: About Reqorsa - Reqorsa consists of a TUSC2 gene expressing plasmid encapsulated in lipid-based nanoparticles, specifically targeting cancer cells while minimizing uptake by normal tissue [8] - Laboratory studies indicate that TUSC2 uptake in tumor cells after Reqorsa treatment is 10 to 33 times higher than in normal cells [8] Group 5: Company Overview - Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes, utilizing its Oncoprex® Delivery System for gene therapy [10] - The company's lead product candidate, Reqorsa, is being evaluated in clinical trials for non-small cell lung cancer and small cell lung cancer, with both programs receiving Fast Track Designation from the FDA [10]